Progenics Pharmaceuticals Inc (PGNX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

ONE WORLD TRADE CENTER NEW YORK, NY 10007

Progenics Pharmaceuticals Inc focuses on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Data based on most recent fiscal year report
Market Cap400.989 Million Shares Outstanding86.42 Million Avg Volume1.374 Million
1-Yr BETA vs S&P TR1.812 Current Ratio6.15 Quick Ratio6.15
View SEC Filings from PGNX instead.

View recent insider trading info

Funds Holding PGNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PGNX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CAMPBELL BRADLEY L CHIEF OPERATING OFFICER

  • Officer
  • Director
370,520 2020-01-15 2

BROADFIN HEALTHCARE MASTER FUND LTD

BROADFIN CAPITAL, LLC

KOTLER KEVIN

  • 10% Owner
2,541,222 2020-01-09 0

FERRANTE KAREN JEAN

  • Director
0 2020-01-02 1

MAEUSLI HEINZ CHRISTOPH

0 2019-12-13 3

ENDE ERIC J

0 2019-12-13 3

BER GERARD

0 2019-12-13 3

MACDOUGALL ANN L.

0 2019-12-13 3

MIMS DAVID W.

0 2019-12-13 3

VELAN CAPITAL, L.P.

ALTIVA MANAGEMENT INC.

VENKATARAMAN BALAJI

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
8,011,733 2019-09-09 4

LTE PARTNERS, LLC

MELKONIAN CAPITAL MANAGEMENT, LLC

LTE MANAGEMENT, LLC

MELKONIAN RYAN

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
1,950,000 2019-09-05 2

SARPANGAL DEEPAK

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
0 2019-08-22 1

COOKE TERENCE

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
40,000 2019-08-22 1

NOHRIA VIRINDER

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
110,000 2019-08-22 1

WILLIAMS NICOLE

0 2019-07-11 1

SCHEINBERG DAVID A

0 2019-07-11 2

CROWLEY PETER J

0 2019-07-11 2

KISHBAUCH MICHAEL D

0 2019-07-11 1

BAKER MARK ROBERT CHIEF EXECUTIVE OFFICER

0 2019-03-01 1

WONG VIVIEN EVP, DEVELOPMENT

0 2019-03-01 1

FABBIO PATRICK CFO

0 2019-03-01 1

TENBARGE BRYCE SVP, COMMERCIAL

0 2019-03-01 1

OSORIO BENEDICT SENIOR VICE PRESIDENT, QUALITY

0 2019-03-01 1

DAS ASHA CHIEF MEDICAL OFFICER

0 2019-02-01 1

HIRT SHELDON SVP, GC & CORP. SEC.

  • Officer
34,993 2018-07-05 0

SUMMER JEFFERY SVP, DIGITAL TECHNOLOGY

0 2018-03-01 0

BAKER CHARLES A

  • Director
0 2018-01-02 0

BRINER KURT W

  • Director
285,978 2017-08-15 0

ISRAEL ROBERT J EXECUTIVE VICE PRESIDENT, MEDI

  • Officer
35,050 2015-06-11 0

MADDON PAUL J

  • Director
0 2015-06-10 0

YOUSSOUFIAN HAGOP CHIEF MEDICAL OFFICER

  • Officer
0 2015-03-07 0

LOVALLO ANGELO WILLIAM JR VICE PRESIDENT FINANCE

  • Officer
0 2015-03-02 0

GOFF STEPHEN P

  • Director
0 2013-06-12 0

OLSON WILLIAM C SENIOR VP, RESEARCH AND DEVELO

  • Officer
0 2013-04-04 0

MCKINNEY ROBERT A SENIOR VP, CFO

  • Officer
0 2012-03-01 0

DALTON MARK F

  • Director
0 2011-07-01 0

BOYD THOMAS A SR. VP, PRODUCT DEV.

  • Officer
47,137 2010-07-01 0

JACOBSON PAUL F

  • Director
125,600 2008-10-22 0

KREMER ALTON B VP, CLINICAL RESEARCH

  • Officer
25,302 2008-04-01 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

MAEUSLI HEINZ CHRISTOPH

2019-12-13 A 16,393 a 16,393 0.00 direct

BER GERARD

2019-12-13 A 16,393 a 16,393 0.00 direct

MACDOUGALL ANN L.

2019-12-13 A 40,000 a 40,000 0.00 direct

MIMS DAVID W.

2019-12-13 A 16,393 a 16,393 0.00 direct

ENDE ERIC J

2019-12-13 A 40,000 a 40,000 0.00 direct

MACDOUGALL ANN L.

2019-12-13 A 36,065 a 36,065 0.00 direct

MAEUSLI HEINZ CHRISTOPH

2019-12-13 A 40,000 a 40,000 0.00 direct

BER GERARD

2019-12-13 A 40,000 a 40,000 0.00 direct

ENDE ERIC J

2019-12-13 A 16,393 a 16,393 0.00 direct

MIMS DAVID W.

2019-12-13 A 40,000 a 40,000 0.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments